Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy

N/ACompletedNCT00911911

Centre Oscar Lambret66 enrolled

Overview

The scope of the trial is to identify proteomic signatures correlated with tumor response to neo-adjuvant chemotherapy.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

Breast Cancer

Interventions

Blood samplingPROCEDURE

Taken at different times : inclusion, at the cycle 4 and at the cycle 6 during the neoadjuvant chemotherapy

BIOPSYPROCEDURE

Biopsy at the moment of inclusion, before neoadjuvant chemotherapy

SURGERYPROCEDURE

Surgery after neoadjuvant chemotherapy

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Women aged more than 18 years * Histologically proven breast carcinoma * Neo-adjuvant chemotherapy with anthracyclines and/or taxanes * No prior chemotherapy * Written informed consent Exclusion Criteria: * Metastatic disease

Locations (5)

Intercommunal Hospital

Annemasse, France

Centre Oscar Lambret

Lille, France

Hopital Saint Vincent

Lille, France

Centre Henri Becquerel

Rouen, France

Geroges PIANTA Hospital

Outcomes

Primary Outcomes

Proteomic analysis by SELDI-TOF on the tumor biopsy and blood samples Histological response according To Chevallier and Sataloff

Time frame: 6 months

Secondary Outcomes

Correlation with node invasion

Time frame: 6 months

Correlation with basal, luminal phenotypes, HER2 status or hormonal status

Time frame: 6 months

Correlation with the response measured by ultrasound after chemotherapy

Time frame: After 3 and 5 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.